Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R.
Wei L, et al. Among authors: johnson cs.
Oncotarget. 2016 Nov 22;7(47):76374-76389. doi: 10.18632/oncotarget.13062.
Oncotarget. 2016.
PMID: 27823983
Free PMC article.